Study results show treatment with tazemetostat, either as monotherapy or in combination, demonstrates promising efficacy and a manageable safety profile among patients with relapsed/refractory follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL).

These data were presented by Eric Wah Sanji, MD, Magnolia Regional Health Center, Corinth, Mississippi, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

Tazemetostat is an EZH2 inhibitor approved for R/R FL and has shown clinical utility in patients with limited treatment options. Researchers conducted a meta-analysis of non-randomized studies evaluating the safety and efficacy of tazemetostat among patients with R/R FL or DLBCL and who had received ≥2 prior lines of therapy.

The primary end points were objective response rate (ORR), progression-free survival (PFS), duration of response (DOR), and safety.

Overall, 8 studies were included which evaluated 306 patients.

Among patients with FL, the ORR was 64.2% (95% confidence interval [CI], 48.9 to 77.7; P = .001; I²=73%), with a mean PFS of 9.68 months (95% CI, 4.46 to 14.90; P <.001; I²=99%). In 2 studies, the reported DOR at 12 months was 84.5%.

For patients with DLBCL, the pooled ORR was 59.4% (95% CI, 23.9 to 87.2; P <.001; I²=84%).

In terms of safety, grade ≥3 treatment-related adverse events occurred in in 13.8% (95% CI, 6.8 to 26.1; I²=15%) of patients and serious adverse events occurred in 5.4% (95% CI, 2.8 to 10.2%; I²=0%).

“Relapsed/refractory FL and DLBCL responds well to tazemetostat in terms of ORR, PFS, and DOR, with a relatively low incidence of severe adverse events making it a viable and promising treatment option,” the researchers concluded. “Additional studies are necessary to confirm these findings and enhance treatment approaches.”

Source:

Sanji EWP, Niba J, Ndemazie NB, et al. Efficacy and safety of tazemetostat in patients with refractory/relapsed follicular lymphoma or diffuse large B cell lymphoma: Systematic review and meta analysis. Presented at 2025 ASCO Annual Meeting. May 30-June 3, 2025; Chicago, IL. Abstract 2004.